Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Zai Lab's NDA for Novel Antibiotic Accepted for China Review

publication date: Feb 10, 2020

Zai Lab reported China's NMPA has accepted for review its NDA for omadacycline, an anti-infective. Omadacycline is a proposed treatment for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Developed by Paratek Pharmaceuticals of the US, omadacycline (Nuzyra®) is a novel tetracycline, designed to overcome tetracycline resistance. It has been available in the US since 2018. To acquire China rights to the anti-infective, Zai paid $7.5 million upfront and agreed to a package of unspecified milestones, plus royalties. More details...

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.